MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 22, 2005; DOI: 10.1124/mol.104.005421


0026-895X/05/6801-41-48$20.00
Mol Pharmacol 68:41-48, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.005421v1
68/1/41    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haider, U. G. B.
Right arrow Articles by Dirsch, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haider, U. G. B.
Right arrow Articles by Dirsch, V. M.

Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2

Ursula G. B. Haider, Thomas U. Roos, Maria I. Kontaridis, Benjamin G. Neel, Dan Sorescu, Kathy K. Griendling, Angelika M. Vollmar, and Verena M. Dirsch1

Department of Pharmacy, Center of Drug Research, University of Munich, Munich, Germany (U.G.B.H., T.U.R., A.M.V., V.M.D.); Cancer Biology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts (M.I.K., B.G.N.); and Department of Medicine, Division of Cardiology, Emory University, Atlanta, Georgia (D.S., K.K.G.)

trans-Resveratrol (RV), a polyphenolic stilbene derivative found in grape skin and other food products, has been proposed to exert beneficial effects in cardiovascular disease. Our group has shown previously that RV inhibits angiotensin II (Ang II)-induced Akt activation and, consequently, vascular smooth muscle cell (VSMC) hypertrophy. In this work, to identify the molecular target of RV, we investigated the impact of RV on early signaling cascades in rat aortic VSMCs triggered by Ang II and epidermal growth factor (EGF). We show that RV does not influence Ang II-mediated transactivation of EGF-receptor but potently inhibits EGF-induced phosphorylation of Akt kinase, suggesting that RV acts downstream of EGF-receptor transactivation in VSMCs. Recent evidence indicates that the adapter molecule Gab1, together with the protein tyrosine phosphatase Shp2, is critically involved in regulating the strength and duration of phosphatidylinositol-3-kinase (PI3K) and Akt activation upon EGF stimulation in fibroblasts. Our results show that stimulation of VSMCs with EGF as well as Ang II leads to a rapid tyrosine phosphorylation of Gab1 and its association with the p85 subunit of PI3K. RV attenuates these processes. Experiments performed in Shp2-deficient fibroblasts revealed that RV does not inhibit EGF-stimulated Akt activation in these cells, suggesting that Shp2 is necessary for the inhibitory effect of RV on the PI3K/Akt pathway. Furthermore, RV treatment activates Shp2. We therefore propose that RV blocks Akt activation in Ang II- and EGF-stimulated VSMCs by activating Shp2, thus preventing interaction between Gab1 and PI3K that is necessary for further signal transduction.


Received July 27, 2004; accepted April 22, 2005

Address correspondence to: Dr. Verena M. Dirsch, Department of Pharmacy, Center of Drug Research, Butenandtstrasse 5–13, D-81377 Munich, Germany. E-mail: verena.dirsch{at}cup.uni-muenchen.de




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Miyazaki, T. Ichiki, T. Hashimoto, K. Inanaga, I. Imayama, J. Sadoshima, and K. Sunagawa
SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1263 - 1269.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. H. Opie and S. Lecour
The red wine hypothesis: from concepts to protective signalling molecules
Eur. Heart J., July 2, 2007; 28(14): 1683 - 1693.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell
The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Yano, D. Suzuki, M. Endoh, T. C. Zhao, J. F. Padbury, and Y.-T. Tseng
A Novel Phosphoinositide 3-Kinase-dependent Pathway for Angiotensin II/AT-1 Receptor-mediated Induction of Collagen Synthesis in MES-13 Mesangial Cells
J. Biol. Chem., June 29, 2007; 282(26): 18819 - 18830.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Ungvari, Z. Orosz, A. Rivera, N. Labinskyy, Z. Xiangmin, S. Olson, A. Podlutsky, and A. Csiszar
Resveratrol increases vascular oxidative stress resistance
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2417 - H2424.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
A. N. Lyle and K. K. Griendling
Modulation of vascular smooth muscle signaling by reactive oxygen species.
Physiology, August 1, 2006; 21: 269 - 280.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics